Moderna, Inc. — Director's Dealing 2022

May 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-05-11

Reporting Person: Bancel Stephane (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-11	Common Stock	S	1473	$123.43	Disposed	5403062	Direct
2022-05-11	Common Stock	S	1239	$124.32	Disposed	5401823	Direct
2022-05-11	Common Stock	S	1688	$125.47	Disposed	5400135	Direct
2022-05-11	Common Stock	S	496	$126.35	Disposed	5399639	Direct
2022-05-11	Common Stock	S	421	$127.30	Disposed	5399218	Direct
2022-05-11	Common Stock	S	865	$128.64	Disposed	5398353	Direct
2022-05-11	Common Stock	S	1186	$129.60	Disposed	5397167	Direct
2022-05-11	Common Stock	S	806	$130.89	Disposed	5396361	Direct
2022-05-11	Common Stock	S	485	$132.23	Disposed	5395876	Direct
2022-05-11	Common Stock	S	169	$133.24	Disposed	5395707	Direct
2022-05-11	Common Stock	S	172	$134.52	Disposed	5395535	Direct
2022-05-11	Common Stock	G	4000	—	Disposed	5391535	Direct
2022-05-12	Common Stock	S	10000	$121.10	Disposed	6894880	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9050372	Indirect

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.90 to $123.88. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.92 to $124.83. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.98 to $125.98. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.00 to $126.65. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.03 to $127.60. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.11 to $129.09. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.26 to $130.18. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.32 to $131.25. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.76 to $132.71. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.91 to $133.53. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.30 to $134.72. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F13: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.

F14: The reported disposition represents a bona fide charitable gift made by the reporting person.

F15: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

F16: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these
securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F17: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.